Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

This study tests whether a new drug called SYS6010 works better than standard platinum-based chemotherapy for people with advanced non-small cell lung cancer (NSCLC) that has a specific gene mutation called EGFR. Participants must have already tried and not responded to targeted EGFR therapies. **You may be eligible if...** - You are 18 to 75 years old - You have locally advanced or metastatic NSCLC with an EGFR mutation - Your previous EGFR-targeted therapy has stopped working - You have at least one measurable tumor on imaging - You are in reasonably good health (able to carry out daily activities) - Your liver, kidney, and blood counts meet required levels **You may NOT be eligible if...** - You have small cell lung cancer, squamous cell carcinoma, or certain other lung cancer subtypes - You have active or untreated brain/spinal cord metastases - You have had a serious heart attack, stroke, or heart failure recently - You have active lung disease (interstitial lung disease or pneumonitis) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.